News | June 28, 2021
Lonza to expand API manufacturing facility in Nansha, China
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Subscribe To Our Newsletter & Stay Updated
